News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2016 Archives

Nov 14, 2016

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Jefferies 2016 London Healthcare Conference to be held at the Waldorf...

More
Nov 9, 2016
Single-agent, anti-tumor activity observed in 7/18 evaluable patients with solid tumors, including one unconfirmed partial response per RECIST 1.1

Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting. NKTR-214 is an...

More
Nov 3, 2016

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2016. Cash and investments in marketable securities at September 30, 2016 were...

More
Oct 28, 2016
Data from Phase 1 dose-escalation trial of NKTR-214 to be presented by lead clinical investigators

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event at the upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting in National...

More
Oct 28, 2016
Five data presentations will showcase Nektar's immuno-oncology candidates, NKTR-214 and NKTR-255

Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations will be delivered at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, which will be held November...

More
Oct 27, 2016

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2016, on Thursday, November 3, 2016, after the close of U.S.-based financial...

More
Oct 19, 2016

Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced the pricing of its previously announced underwritten public offering of $175.5 million in aggregate gross proceeds, or 13,000,000...

More
Oct 17, 2016

Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced that it has commenced an underwritten public offering of $175 million of shares of its common stock. In connection with this offering,...

More
Sep 27, 2016

Nektar Therapeutics (Nasdaq: NKTR) announced that it will host a conference call to discuss today's announcement of the new clinical collaboration with Bristol-Myers Squibb. The call will begin at...

More
Aug 3, 2016

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2016. Cash and investments in marketable securities at June 30, 2016 were $274.9...

More
Jul 27, 2016

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2016, on Wednesday, August 3, 2016, after the close of U.S.-based financial markets....

More
Jun 6, 2016

Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being evaluated in cancer patients with solid tumors in...

More
Jun 2, 2016

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies 2016 Global Healthcare Conference in New York City on...

More
Jun 2, 2016
John Nicholson named Senior Vice President & Chief Operating Officer of Nektar; Gil M. Labrucherie named Senior Vice President & Chief Financial Officer of Nektar

Nektar Therapeutics (NASDAQ: NKTR) announced today that John Nicholson has been named Senior Vice President & Chief Operating Officer and Gil M. Labrucherie has been named Senior Vice President &...

More
Jun 1, 2016

Nektar Therapeutics (Nasdaq: NKTR) today announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug therapy, ONZEALD (etirinotecan pegol,...

More
May 3, 2016

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2016. Cash and investments in marketable securities at March 31, 2016 were $288.3...

More
Apr 28, 2016

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2016, on Tuesday, May 3, 2016, after the close of U.S.-based financial markets. Howard...

More
Apr 18, 2016

Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for the company's investigational immuno-stimulatory cytokine therapy, NKTR-214, which demonstrate both its activity as a...

More
Apr 4, 2016
ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] approved for treatment of patients 12 years and older with hemophilia A in Japan

BANNOCKBURN, Ill.--(BUSINESS WIRE)-- Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and...

More
Mar 3, 2016

Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming Cowen and Company 36th Annual Health Care Conference in Boston, Massachusetts on Wednesday, March 9, 2016 at 8:40 a.m....

More
Mar 1, 2016

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2015. Cash and investments in marketable securities at December 31, 2015 were

More
Feb 26, 2016

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2015, on Tuesday, March 1, 2016, after the close of U.S.-based financial...

More
Feb 25, 2016
- ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], currently FDA-approved for adolescent and adult hemophilia A patients 12 years and older, offers proven prophylaxis with a simple, twice-weekly dosing schedule

Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today...

More
Feb 1, 2016
New Paper Documents Durable Anti-Tumor Efficacy, Safety and Immune Mechanism of Action of NKTR-214 in Multiple Tumor Models as well as a Favorable Safety Profile in Non-Human Primates (NHPs)

Nektar Therapeutics (Nasdaq: NKTR) today announced the publication in Clinical Cancer Research of pre-clinical findings for NKTR-214. The paper, titled "NKTR-214, an Engineered Cytokine with...

More
Jan 6, 2016

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 34th Annual J.P. Morgan Healthcare Conference in San Francisco...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide